MIRIKIZUMAB – THE EFFICACY OF TREATMENT IN INFLAMMATORY BOWEL DISEASE
Abstract
Mirikizumab is a humanized monoclonal antibody directed against the p19 subunit of interleukin IL-23. In recent years, it has been the subject of numerous clinical trials as a potential new therapy for inflammatory bowel diseases, including Crohn’s disease and ulcerative colitis. Additionally, mirikizumab has been evaluated in clinical trials as a possible treatment for plaque psoriasis. Clinical trial results in ulcerative colitis led to its approval in the European Union, the United States, Canada, and Japan for the treatment of adult patients with moderately to severely active disease. Despite promising clinical trial outcomes, mirikizumab has not yet been approved for the treatment of Crohn’s disease. This review focuses on summarizing findings from clinical trials investigating mirikizumab in inflammatory bowel diseases. The information is derived from scientific publications indexed in PubMed, searched using the terms “mirikizumab” and “IL-23” and published up to February 2025, as well as from published clinical trial results on mirikizumab.
References
Tan ZY, Bealgey KW, Fang Y, Gong YM, Bao S. Interleukin-23: immunological roles and clinical implications. Int. J. Biochem. Cell Biol. 2009, 41(4), 733-5 DOI: 10.1016/j.biocel.2008.04.027
Duvallet E, Semerano L, Assier E, Falgarone G, Boissier MC. Interleukin-23: a key cytokine in inflammatory diseases. Ann. Med. 2011, 43(7), 503- 11, DOI:10.3109/07853890.2011.577093
Tian Z, Zhao Q, Teng X. Anti-IL23/12 agents and JAK inhibitors for inflammatory bowel disease. Front. Immunol. 2024, 15, Art. No: 1393463. DOI: 10.3389/fimmu.2024.1393463
Geremia A, Arancibia-Cárcamo CV, Fleming MPP, Rust N, Singh B, Mortensen NJ, Travis SPL, Powrie F. IL-23–responsive innate lymphoid cells are increased in inflammatory bowel disease. J Exp Med (2011) 208 (6): 1127–1133. doi.org/10.1084/jem.20101712
McGovern D, Powrie F. The IL23 axis plays a key role in the pathogenesis of IBD. Gut 2007; Oct;56(10):1333–1336. doi: 10.1136/gut.2006.115402
Tang, C, Chen S, Qian H, Huang W. Interleukin-23: as a drug target for autoimmune inflammatory diseases. Immunology 2012, 135(2), 112-124. DOI: 10.1111/j.1365-2567.2011.03522.x
Aggarwal S, Ghilardi N, Xie M.H, de Sauvage F.J, Gurney A.L. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 2003, 278(3), 1910-1914. DOI:10.1074/jbc.M207577200
Aggarwal, S, Gurney A.L. IL-17: prototype member of an emerging cytokine family. J. Leukoc. Biol. 2002, 71(1), 1-8. DOI: 10.1189/jlb.71.1.1
Yen D, Cheung J, Scheerens H, et al.. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 2006; 116: 1310-6.
Levin A.A, Gottlieb A.B. Specific targeting of interleukin-23p19 as effective treatment for psoriasis. J. Am. Acad. Dermatol. 2014, 70(3), 555-561. DOI: 10.1016/j.jaad.2013.10.043
Lees C.W, Barrett J.C,Parkes M, Satsangi J. New IBD genetics: common pathways with other diseases. Gut 2011, 60(12), 739-753 DOI:10.1136/gut.2009.199679
Steere B, Beidler C, Martin A, Bright, S, Kikly K, Benschop R.J. Generation and Characterization of Mirikizumab, a Humanized Monoclonal Antibody Targeting the p19 Subunit of IL-23. J. Pharmacol. Exp. Ther. 2023, 387(2), 180-187. DOI:10.1124/jpet.122.001512
Elson CO, Cong Y, Weaver CT, Schoeb TR, McClanahan TK, Fick RB, et al. Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology 2007, 132(7), 2359-70. DOI:10.1053/j.gastro.2007.03.104
Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 1998; 115: 182-205.
Ahmad T, Tamboli CP, Jewell D, Colombel JF. Clinical relevance of advances in genetics and pharmacogenetics of IBD. Gastoenterology 2004; 126: 1533-49.
Hammerhøj A, Boye TL, Langholz, E, Nielsen OH. Mirikizumab (Omvoh™) for ulcerative colitis. Trends Pharmacol. Sci. 2024, 45(3), 281-2. DOI:10.1016/j.tips.2024.01.001
Rao SS, Holdsworth CD, Read NW. Symptoms and stool patterns in patients with ulcerative colitis. Gut 1988, 29(3), 342-5. DOI:10.1136/gut.29.3.342
Feuerstein JD Cheifetz AS. Ulcerative colitis: epidemiology, diagnosis, and management. Mayo Clin. Proc. 2014, 89(11), 1553-1563. DOI:10.1016/j.mayocp.2014.07.002
Tontini GE, Vecchi M, Pastorelli L, Neurath MF, Neumann H. Differential diagnosis in inflammatory bowel disease colitis: state of the art and future perspectives. World J. Gastroenterol. 2015, 21(1), 21-46. DOI:10.3748/wjg.v21.i1.21
Danese S, Fiocchi C. Etiopathogenesis of inflammatory bowel diseases. World J. Gastroenterol. 2006, 12(30), 4807-12. DOI:10.3748/wjg.v12.i30.4807
Dragasevic S, Stankovic B, Sokic-Milutinovic A, Milosavljevic T, Milovanovic T, Lukic S, et al. Importance of TLR9-IL23-IL17 axis in inflammatory bowel disease development: Gene expression profiling study. Clin. Immunol. 2018, 197, 86-95. DOI:10.1016/j.clim.2018.09.001
Raine T, Bonovas S, Burisch J, Kucharzik T, Adamina M, Annese V, et al. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. J. Crohns Colitis 2021, 16(1), 2-17. DOI:10.1093/ecco-jcc/jjab178
Sandborn WJ, Ferrante M, Bhandari BR, Berliba E, Feagan BG, Hibi T, et al. Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis. Gastroenterology 2020, 158(3), 537-549.e10. DOI: 10.1053/j.gastro.2019.08.043
Sandborn WJ, Sands, BE, Vermeire S, Leung Y, Guo X, Modesto I, et al. Modified Mayo score versus Mayo score for evaluation of treatment efficacy in patients with ulcerative colitis: data from the tofacitinib OCTAVE program. Therap. Adv. Gastroenterol. 2022, 15, Art. No: 7562848221136331. DOI: 10.1177/17562848221136331
Sandborn WJ, Ferrante M, Bhandari BR, Berliba E, Hibi T, D'Haens GR, et al. Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative Colitis. Clin. Gastroenterol. Hepatol. 2022, 20(1), 105-115.e14. DOI: 10.1016/j.cgh.2020.09.028
II phase clinical trial of mirikizumab in UC [accesed and cited 2024 27.07]. Available from: https://clinicaltrials.gov/study/NCT02589665.
Badanie LUCENT-1 - III faza badań klinicznych mirikizumabu w leczeniu UC [accesed and cited 2024 27.07]. Available from: https://clinicaltrials.gov/study/NCT03518086.
D’Haens G, Kobayashi T, Morris N, Lissoos T, Hoover A, Li X, et al. OP26 Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active Ulcerative Colitis: Results from the Phase 3 LUCENT-1 study. J. Crohns Colitis 2022, 16(Supplement_1), i028-i029. DOI: 10.1093/ecco-jcc/jjab232.025
Efficacy and Safety of Mirikizumab as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Study. Gastroenterol. Hepatol. 2022; 18(4 Suppl 1), 7-8.
D’Haens G, Dubinsky M, Kobayashi T, Irving PM, Howaldt S, Pokrotnieks J, et al. Mirikizumab as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 2023, 388(26), 2444-2455. DOI:10.1056/NEJMoa2207940
A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 2). [accesed and cited 2024 27.07]. Available from: https://clinicaltrials.gov/study/NCT03524092
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3). [accesed and cited 2024 27.07]. Available from: https://clinicaltrials.gov/study/NCT03519945.
Sands BE, D’Haens, G, Clemow, DB, Irving, PM, Johns, JT, Hunter, T, et al. Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study. Inflamm. Bowel Dis. 2024, 30(6), 1044-1045. DOI: 10.1093/ibd/izae024
Information provided by the European Medicines Agency (EMA) concerning Omvoh (mirikizumab). Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/omvoh
The decision of the Japanese Pharmaceuticals and Medical Devices Agency to approve Omvoh (mirikizumab) for marketing in Japan for the treatment of moderate to severe UC in adults. Available from: https://www.pmda.go.jp/PmdaSearch/iyakuDetail/GeneralList/23994A5.
FDA Approves Lilly's Omvoh™ (mirikizumab-mrkz), A First-in-Class Treatment for Adults with Moderately to Severely Active Ulcerative Colitis. Available from: https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-omvohtm-mirikizumab-mrkz-first-class
Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product - Canada. Available from: https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SBD1695821197450.
Baumgart DC, Sandborn WJ. Crohn's disease. The Lancet. 2012, 380(9853), 1590-605.DOI:10.1016/S0140-6736(12)60026-9
Shanahan F. Crohn's disease. The Lancet. 2002, 359(9300), 62-9. DOI: 10.1016/S0140-6736(02)07284-7
A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's Disease (SERENITY). Available from: https://clinicaltrials.gov/study/NCT02891226.
Avedillo-Salas A, Corral-Cativiela S, Fanlo-Villacampa A, Vicente-Romero J. The Efficacy and Safety of Biologic Drugs in the Treatment of Moderate-Severe Crohn's Disease: A Systematic Review. Pharmaceuticals (Basel) 2023, 16(11), ARt. No: 1581. DOI: 10.3390/ph16111581
Sands BE, Peyrin-Biroulet L, Kierkus J, Higgins PDR, Fischer M, Jairath V, et al. Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's Disease. Gastroenterology 2022, 162(2), 495-508. DOI:10.1053/j.gastro.2021.10.050
A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (VIVID-1). Available from: https://clinicaltrials.gov/study/NCT03926130.
Aslam M, Ali MH, Irfan H. Mirikizumab: A promising breakthrough in Crohn's disease treatment. Health Sci. Rep. 2024, 7(8), Art. No: e2294. DOI:10.1002/hsr2.2294
Ferrante M, Danese S, Chen M, D'Haens G, Ghosh S, Hisamatsu T, et al. OP05 Primary efficacy and safety of mirikizumab in moderate to severe Crohn’s Disease: results of the treat-through VIVID 1 study. J. Crohns Colitis 2024, 18(Supplement_1), i7-i9. DOI: 10.1093/ecco-jcc/jjad212.0005
Jairath V, Sands BE, Bossuyt P, Farraye F, Ferrante M, Hisamatsu T, et al. OP35 Efficacy of mirikizumab in comparison to ustekinumab in patients with moderate to severe Crohn’s disease: Results from the phase 3 VIVID 1 study. J. Crohns Colitis 2024, 18(Supplement_1), i62-i4. DOI:10.1093/ecco-jcc/jjad212.0035
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease (VIVID-2). Available from: https://clinicaltrials.gov/study/NCT04232553.
Omvoh - opinion on variation to marketing authorization. Available from: https://www.ema.europa.eu/en/medicines/human/variation/omvoh
Views:
50
Downloads:
17
Copyright (c) 2025 Adam Niedziela, Dominik Domoń, Dominika Domanowska, Antoni Liebert, Natalia Klimek, Hanna Wilska, Martyna Kaplińska, Bartosz Rutka, Karolina Niewczas, Adrianna Brzozowska
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
